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INTRODUCTION
Neuroblastoma is the most common extracranial solid tumor in
childhood in high-income countries (HIC), where it accounts for
10% of pediatric cancers [1]. However, in low- and middle- income
countries (LMIC) with population-based registries, it accounts for
only 1–3% of cancers, and in most LMIC its true incidence is
unknown [2–4]. The limited available data suggest that in LMIC,
late diagnosis, lack of access to accurate staging, risk stratification,
optimal treatment, and abandonment lead to survival rates much
lower than those in HIC [3,5–9]. With the Pediatric Oncology in
Developing Countries (PODC) committee of the International
Society of Pediatric Oncology (SIOP) working group for adapted
treatment regimens, we developed these recommendations for
adapted management of neuroblastoma.
This manuscript focuses on neuroblastoma, since general
principles of adapted therapy have been previously reported [10–
13]. Optimizing treatment in LMIC at centers with variable
capabilities and infrastructure requires adapting diagnostic meth-
ods, risk stratification, and therapy for children with neuroblastoma
based on available resources [10–13]. In Table I, we defined each
setting based on the minimal required resources to facilitate
appropriate diagnosis and risk-stratified, intensity-adapted treat-
ment. We have used the terminology ‘‘Setting 1’’ to represent
centers with minimal resources, but with access to care and
treatment with curative intent, while ‘‘Setting 4’’ represents centers
with state-of-the-art diagnostic and treatment capability for high-
risk neuroblastoma. Many countries, especially low-income
countries (LIC), have extreme heterogeneity in resources available
where some privately-funded centers may represent Setting 3, while
nearby institutions may be Setting 1. A consistent approach to
diagnosis and treatment that is adapted to local conditions and
resource availability will improve the care of children in LMIC.
METHODS
A Global Neuroblastoma Network (GNN) subcommittee of
pediatric oncologists from LMIC and HIC reviewed published
evidence about treatment strategies for low-risk, intermediate-risk,
and high-risk neuroblastoma and applied these strategies during
weekly online Global Neuroblastoma Network (GNN) case
discussions held via www.Cure4Kids.org. The subcommittee
consensus recommendations are based on review of published
evidence (using PubMed 1) for neuroblastoma diagnostics, risk
assessments, prognostic markers, and treatment strategies com-
bined with expert opinion about neuroblastoma and healthcare
delivery in LMIC. The draft was reviewed by peers in HIC and
LMIC and presented to a broad group of pediatric solid tumor
experts via web conferences of the SIOP PODC working group on
adapted treatment regimens, the annual SIOP meeting, and the
GNN weekly online multidisciplinary conferences [14].
Neuroblastoma is the most common extracranial solid tumor in
childhood in high-income countries (HIC), where consistent
treatment approaches based on clinical and tumor biological risk
stratification have steadily improved outcomes. However, in low-
and middle- income countries (LMIC), suboptimal diagnosis, risk
stratification, and treatment may occur due to limited resources and
unavailable infrastructure. The clinical practice guidelines outlined
in this manuscript are based on current published evidence and
expert opinions. Standard risk stratification and treatment explicitly
adapted to graduated resource settings can improve outcomes for
children with neuroblastoma by reducing preventable toxic death
and relapse. Pediatr Blood Cancer 2015;62:1305–1316.
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DIAGNOSIS
The diagnosis of neuroblastoma is based on pathology with
immunohistochemistry (IHC) complemented by urine catechol-
amines. In all settings, physical examination, basic laboratory,
radiographic, and pathologic evaluation should be performed
(Table I). Neuroblastoma should be suspected in children with
cervical, mediastinal, paraspinal, abdominal or pelvic masses, and
the diagnosis made by either biopsy of the primary tumor or by
identification of characteristic tumor cells in the bone marrow.
The presence of hypertension may suggest neuroblastoma orWilms
tumor. Elevated urine catecholamines, including urine homovanil-
lic acid (HVA), vannilylmandelic acid (VMA), strongly suggest the
diagnosis, and is helpful to distinguish among small round blue cell
tumors [15]. Conversely, if urine catecholamines are not available
or are non-diagnostic, neuroblastoma can be differentiated from
other small round blue cell tumors using IHC staining for tyrosine
hydroxylase, CD56, and synaptophysin. Alternative diagnosis
should be considered for IHC positive staining for leukocyte
common antigen CD45 in lymphoma, CD99 in Ewing sarcoma, and
desmin andmyogenin in rhabdomyosarcoma [16]. In Setting 1, IHC
is usually not available, and the treating doctor will have to rely on a
combination of the pathologic appearance and typical clinical
features (e.g., age at diagnosis, symptoms, sites of disease, sites of
metastases, lack of response to glucocorticoid therapy).
STAGING AND RESPONSE EVALUATION
Accurate staging and response evaluation are essential for
determining treatment and prognosis (Table I). In all settings,
bilateral bone marrow aspirate and biopsy should be performed to
detect bone marrow metastases, which occur in 70% of metastatic
neuroblastoma patients [17]. Radiologic and surgical staging depend
on locally available resources: Advance imaging, includingmagnetic
resonance imaging (MRI), 123I-metaiodobenzylguanidine (123I-
mIBG) scans, and 18FDG-PET have increased the accuracy of
diagnosis and staging and facilitate local control with surgery and
radiotherapy, but due to high cost, are inconsistently available in
LMIC [18,19]. Surgical staging of the primary tumor is according to
the International Neuroblastoma Staging System (INSS-Supplemen-
tal Appendix I) [20]. The recent International Neuroblastoma Risk
Group (INRG-Supplemental Appendix I) staging system is a simpler,
radiologic staging,which is not influencedbydegree of resection [21].
Setting 1
Staging and response assessment depend on imaging studies and
bilateral bone marrow biopsy with simple hematoxylin and eosin
staining to document presence of disease (Table I). Plain
radiographs and abdominal ultrasound can document the extent
of thoracic and abdominal disease [22], but are suboptimal for
staging and pre-operative planning due to their lack of sensitivity to
detect small metastatic lesions in lymph nodes or lungs. Evaluation
for bone disease should include bone radiographs (e.g., a skeletal
survey), with the understanding that plain radiographs are less
sensitive (26% lesions identified) than bone scan (59% lesions
identified) to detect skeletal involvement [23,24].
Setting 2
Computerized tomography (CT) of neck, chest, abdomen, and
pelvis with intravenous contrast combined with 99mTc phosphonate
nuclear imaging provides greater sensitivity of anatomic location,
associated radiologic risk factors for surgery, and metastasis
(Table I). CT is more sensitive for bone involvement than plain
radiographs. If spinal involvement is suspected, magnetic reso-
nance imaging (MRI), if available, should be obtained to assess
invasion of the neural foramina and spinal cord compression.
Setting 3
In Setting 3, the neuroblastoma staging and risk classification
should include CT of neck, chest, abdomen, and pelvis with
intravenous contrast; MRI of sites with suspected spinal involve-
ment and sites where tumor extent is not well defined by CT; and
123I- mIBG scans, or 18FDG-PET (Table I). 123I- mIBG, which is
taken up via the norepinephrine transporter in 90% of patients with
neuroblastoma [19] is the most sensitive and specific test for
metastatic disease in bone or soft tissue. An 18FDG-PET scan is
also sensitive, but less specific than mIBG for neuroblastoma but
can be used in patients whose tumors are 123I- mIBG negative or
when 123I- mIBG scans are unavailable [18].
RISK STRATIFICATION
In the past two decades, risk stratification using clinical and
tumor biological features has facilitated intensity-adjusted neuro-
blastoma therapy with resultant improvements in outcomes and
decreased complications in HIC [22,25–28]. Established prognostic
markers utilized over the past two decades include clinical features
such as stage, age, serum lactate dehydrogenase (LDH), serum
ferritin; tumor histological classification; and tumor biologic
features of MYCN gene amplification status, DNA ploidy and
segmental chromosomal aberrations [29–31].
Histologic classification according to International Neuroblas-
toma Pathology Classification (INPC) could be helpful in all
settings to guide risk stratification [15]. Unfortunately, INPC has
been underutilized in LMIC due to shortages of trained pathologists
familiar with pediatric malignancy and INPC. Fluorescent in situ
hybridization (FISH) or RT-PCR for tumor MYCN gene amplifica-
tion is desirable, but are most essential in risk stratification for
children with stage 4 tumor in patients <18 months of age, and for
all stage 3 tumors. DNA ploidy is most helpful in infants without
MYCN amplified disease, who have stage 4 or 4 S disease, as
patients with diploid tumors have significantly lower survival, and
may require more intensive therapy [32,33].
Prognosis
In HIC, children with localized disease and favorable biology
tumors (INSS 1, 2, and 4 S or INRG L1, and MS) have an overall
survival (OS) of 96% with surgery alone, or in some cases
observation only [20–22,31,34,35]. In the intermediate risk group,
comprising of infants withmetastatic disease or infants and children
with unresectable (INSS 3 or INRG L2) disease without tumor
MYCN amplification, the OS remains greater than 90% when
treated with 3–6 months of outpatient chemotherapy of moderate
intensity [26]. Yet in LMIC, survival rates even for localized disease
is usually lower [5–7] perhaps due to inaccurate staging or risk
stratification. Lack of access to biologic risk classification may lead
to over-treatment and higher risk of death from aggressive surgical,
toxicity, or treatment abandonment. Treating high-risk disease,
comprised mainly of children >18 months with stage 3 and 4
Pediatr Blood Cancer DOI 10.1002/pbc
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disease and any stage with MYCN amplified tumors is challenging
even in HIC, with OS of 40% using modern protocols in settings
with excellent supportive care [36–40]. Due to economic, social,
and health system factors, high-risk patients typically form a greater
proportion of patients diagnosed with neuroblastoma in LMIC than
HIC. In LMIC, especially in Setting 1 centers, high risk patient are
often not treated with curative intent, since expected survival rates
would be <10% [5,6].
Adapted Risk Stratification
Guidelines for risk stratification are shown in Table II. Age and
stage continue to be the strongest clinical prognostic factors for
neuroblastoma. Age<18 months implies favorable disease, even in
the presence of metastases, provided there is no tumorMYCN gene
amplification [31,41]. In Setting 3, where INPC classification may
be performed, toddlers age 12–18 months with stage 4 disease with
Unfavorable Histology (if available) and/or diploidy/hypodiploidy
should be considered to have high-risk disease even withoutMYCN
amplification. However, toddlers with stage 3 disease without
MYCN amplification should still be treated on the intermediate risk
protocol, as the benefit of transplant is not clearly defined [42].
Children 18 months of age with stage 4 disease should be
treated as high-risk, without further need for biologic or clinical
markers [31].
One significant limitation in LMIC is the inability to assess
MYCN amplification in some centers, despite the fact that it is
present in approximately 25% of patients [43] and is critical to
differentiate between intermediate and high-risk disease for
patients <18 months with stage 4 disease, and for all patients
with stage 3 disease [31]. AlthoughMYCN amplification in stage 1,
2, and 4 S tumors could potentially change the risk group, it is
uncommon in this group [25]. When MYCN assessment is not
available, we would consider use of serum LDH and serum ferritin
as surrogate markers forMYCN amplification in INSS stage 3 and 4
disease [44]. In Children’s Cancer Group Study 3891, 70 eligible
newly diagnosed patients with Evans stage 3 diseasewere evaluated
for ferritin as a prognostic marker, demonstrating 5-year EFS
38 9% for patients with ferritin >143 ng/ml versus 78 8% for
those with ferritin<143 ng/ml [42,45]. A review of INRG database
identified 1483 INSS stage 3 patients, of which ferritin was known
in 666 patients, and LDH in 959 patients. Five-year EFS associated
with ferritin <96 ng/ml versus 96 ng/ml was 77 3% versus
61 4%, respectively (P¼<0.0001), while the 5-year EFS for
patients with LDH<580U/L versus580U/L was 78 2% versus
67 3%, respectively (P¼<0.0001) [42]. Therefore, any patient
with stage 3 disease and those <18 months with stage 4 disease
whose LDH and/or ferritin exceed this thresholdmay be stratified as
high-risk [33,42,45–47]. If we had to determine a single marker,
LDH would be arbitrarily used, as that has the most literature
support. The reported threshold at which elevated LDH serves as a
prognostic marker varies from >580 IU/L to >1000 IU/L [42,48];
therefore, we recommend the intermediate level of 750 IU/L to
intensify therapy in LMIC when MYCN status is unknown. The
reported threshold at which elevated ferritin has been shown
to affect outcome has varied, from >92 ng/ml to >142 ng/ml
[31,48,49]; therefore we recommend considering a pre-treatment
ferritin 120 ng/ml to intensify therapy in LMIC when MYCN
status is unknown. For both ferritin and LDH, we chose to use
an intermediate rather than the highest value as the proposed
threshold, acknowledging differences in laboratory ranges while
noting that the largest INRG analysis used the lower value.
LDH and ferritin assessments are of uncertain prognostic
significance in patients with INSS 1, 2, or 4 S tumors, and therefore
not recommended for changing the risk category in those
patients [22,25,28,31,34].
TREATMENT GUIDELINES
Treatment guidelines according to risk group and setting are
outlined in Table II.
Low Risk Disease
In patients with INSS 1 and 2 tumors, the outcome is excellent,
with >95% 3 year OS [27,50]. Regardless of setting, surgical
resection is sufficient for asymptomatic patients whose tumor is
largely (>50%) resected, even if some residual tumor remains.
Patients with tumor resection can be monitored without further
therapy, with ultrasound or CT every 3months for the 1st year and
then every 6months until 2 years after diagnosis [27]. Perinatal
adrenal neuroblastoma (Very LowRisk—VLR) patients, with small
adrenal masses detected before birth or within the first six post-natal
months, have an especially favorable outcome with >95% 4 year
OS, without any surgical or medical intervention [35]. We
recommend monitoring these patients with ultrasonography and
physical exam every 6–8weeks, until the mass resolves, or until
significant growth warrants surgical resection. Occasionally, these
patients will progress to INSS 4 S, but they can be safely observed as
long as they remain asymptomatic [51,52].
Infants with stage 4 S asymptomatic disease have an overall
5 years survival 100% for those patients that did not require
chemotherapy [51]. For patients with symptomatic stage 4 S
neuroblastoma with hepatic dysfunction, coagulopathy, respiratory
compromise, or renal impairment, we recommend treatment with
intermediate risk therapy. Infants younger than 3months with
hepatomegaly evenwithout symptoms deserve prompt intermediate
risk treatment until symptoms abate due to the higher risk of death at
this age [33,51].
Intermediate Risk Disease
There have been significant advances in the therapies for
children with intermediate risk neuroblastoma, allowing de-
intensification of therapy while maintaining survival. Children
with stage 3 intermediate risk neuroblastoma or infants with stage 4
were treated in the 1990swith cisplatin, etoposide, doxorubicin, and
cyclophosphamide over 9months, with a 4-year EFS of 100% for
favorable stage 3 [53] and 3-year EFS>93% for infants with INSS
4, MYCN-Non amplified disease [54]. The poor prognostic
indicators identified in the infant group were diploid and/or
MYCN-amplified tumors [32,55]. A French cooperative trial
showed that INSS 3 infants without MYCN gene amplification
had a 94 5% EFS with moderate-intensity chemotherapy [56]. A
large INRG report showed that patients with INSS stage 3 tumors
without MYCN amplification had an 81% 5-year EFS [42].
Therapy has since been modified to shorten the course of
treatment, substitute carboplatin for cisplatin, and decrease the
cumulative doses of active agents by 60% in an effort to decrease
toxicities, hospital stay, and costs, while maintaining survival
outcomes, with 88%3-year EFS and 96%OS [26]. In settings where
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carboplatin is unavailable or is cost-prohibitive, cisplatin can be an
alternative. Table III outlines a well-tolerated intermediate-risk
therapy suitable for each setting [26]. We recommend dose
reduction as outlined in Table II according to availability of
resources given the typically favorable outcome and potential need
to conserve blood products.
Aggressive surgery may cause significant morbidity in patients
with intermediate risk neuroblastoma. Of 235 children with
intermediate risk group on the COG A3961 trial, 28% had surgical
complications including major hemorrhage, vascular and renal
injuries, and intra-operative need for organ resection [26]. Subse-
quent pilot investigations showed that intermediate risk patients
will often mature without progression despite residual unresected
tumor [57]. Given the high survival rate for the intermediate group
regardless of resection extent [49], we recommend chemotherapy
for 4–8 cycles depending on control of metastases and tumor
reduction with conservative surgery performed if needed to
achieve >50% primary tumor response. Radiation therapy is not
recommended even in the setting of residual disease. Patients can be
monitored with ultrasound or CT every 3-months for the 1st year
and then every 6months until 2 years after diagnosis.
High Risk Disease
Despite numerous advances and multimodal therapies in the
treatment of children with neuroblastoma, those with high-risk
disease continue to be our greatest challenge. The incorporation
of three distinct phases of therapy has improved outcome for
high-risk neuroblastoma: intensive induction treatment, myeloa-
blative chemotherapy with autologous hematopoietic stem cell
rescue, and treatment of MRD [58–60]. The goal of induction
therapy is to achieve maximum reduction of tumor burden,
including reduction of metastatic bone marrow, and bone disease
within a timeframe that will minimize the risk of developing
resistant tumor clones and clinical progression. Subsequently,
potentially resistant residual tumor is treated with high-dose
myeloablative therapy followed by autologous hematopoietic
stem cell transplantation (ASCT), which has been shown to
significantly improve EFS [58]. The relapse rate of greater than
40% even after such therapies has led to post-transplant treatment
for MRD-positive patients using isotretinoin and monoclonal
anti-GD2 antibodies [39,58,59].
Due to the lack of transplant expertise, reduced access to blood
products and pheresis, and difficulty supporting patients through the
period of myelosuppression, few Setting 1 centers in LMIC have
attempted curative treatment of high-risk neuroblastoma, and have
commonly prescribed palliative care. Furthermore, the cost of
isotretinoin and lack of access to monoclonal anti-GD2 antibody
impede effective MRD treatment in some LMIC. However, a
coordinated treatment approach based on resource capabilities can
improve outcome for these children progressively, and will
eventually lead to overall improvement in supportive care and
therapy of childhood cancer. We propose a graduated intensity plan
for high-risk patients in different LMIC settings (Table IV).
Induction and Local Control
No single chemotherapy induction regimen has proven to be
superior for induction response and EFS in high-risk neuroblastoma.
All regimens reported todate employmulti-agent chemotherapywith
a platinum agent, alkylator therapy such as cyclophosphamide,
topoisomerase therapy, usually with etoposide or less frequently,
doxorubicin, and vincristine. Initial reports suggested that increasing
dose intensity might improve response rate, but this has not been
borne out in single arm trials which all showed response rates
from 70 to 80% [39,61–63]. The dose-intensive rapid COJEC [64]
did show an improvement in EFS compared in a randomized trial
to OPEC–OJEC, though the 3-year EFS of 31% was not better
than that reported with other North American and European
regimens [40].
Given the increased need for supportive carewithmore intensive
regimens and without significant benefit expected for patients
without the option ofmyeloablative therapy, we have recommended
induction regimens in Setting 1 using a regimen with low dose
metronomic oral cyclophosphamide 25mg/m2 daily (max 50mg) or
oral etoposide 50mg/m2/day for palliation of pain and improve-
ment of quality of life, High Risk Setting 1 (HR-1) [65,66]. An
alternate approach non-curative therapy would entail administering
1–2 cycles of intermediate risk chemotherapy and local radiation to
the primary tumor bed (dosing per Tables III and V) to allow for
some tumor reduction, pain relief and improved quality of life.
Aggressive pain management is strongly recommended, as end-of-
life bone pain can be significant [67].
For Setting 2, we recommend either the same regimen used for
intermediate risk patients, (Table III), for 8 cycles or modified-
Pediatric Oncology Group (POG) 9341 induction regimen,
(Table IV) [26,36]. For Setting 3, we suggest the modified-
POG 9341 induction regimen, which is more intensive than prior
French CAdO-PE [68], and has fewer reported acute toxicities
than N7 [63] or the SIOPEN rapid COJEC [40]. It optimizes
platinum, uses less doxorubicin, and has shorter hospitalization
(primarily given in a day hospital) and higher response rate than
the CCG 3891 protocol [58]. This protocol is currently being used
in Morocco for high-risk patients and has been tolerable in >60
patients without toxic death [69]. An alternative option is to
administer the OPEC–OJEC regimen that incorporates more
carboplatin but avoids doxorubicin; although response rates are
lower than those reported for POG 9341 [40]. Surgery to resect
the primary tumor is recommended after the 4th or 5th induction
cycle in patients, whose metastases have responded significantly
to chemotherapy, including either a complete metastatic response
or a partial response (PR) and fewer than six residual bone
metastases that might be treated with radiotherapy. In a review of
patients with high risk neuroblastoma on the CCG A3891 trial, a
statistically significant improvement was noted in patients with
stage 4 neuroblastoma achieving complete remission after surgery
with a 5 year EFS 26% 4% versus 19% 3% [70] although
there are conflicting evidence as to the benefit of complete
resection when radiotherapy is also incorporated [71,72]. Given
the minimal likely benefit, we recommend avoiding mutilating
surgery likely to risk major complications in LMIC and instead
using radiation therapy to control unresectable primary tumor and
residual bone metastases.
The decision to proceed to amore intensive consolidation should
be based on the response to induction chemotherapy. Multiple
analyses of myeloablative regimens show that the outcome is
significantly better for patients who have achieved at least a partial
response at the end of induction [73], and preferably a good partial
response in metastases as manifested by a low MIBG Curie
score [74].
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Consolidation
The recommended consolidation for curative intent is myeloa-
blative therapy with ASCT, based on three randomized
trials [39,75,76].
Preliminary results from the European SIOP-EN HR NBL-1
randomized phase III trial comparing busulfan and melphalan (Bu/
Mel) versus carboplatin, etoposide, and melphalan (CEM) as a
preparative regimen for autologous transplant, showed improved
survival in patients treated on the Bu/Mel arm [77–79]. Due to its
lesser toxicity and apparently better EFS, we recommend that
Setting 3 centers with transplant capabilities utilize either BuMel,
(Supplemental Appendix II), or consider melphalan alone (180mg/
m2), as this is the active agent that has been the backbone of almost
all neuroblastoma transplant regimens, and was successful in the
first randomized trial [76]. One caveat for those utilizing the Bu/Mel
regimen is the higher risk of sinusoidal obstructive syndrome
(SOS), which may be more severe in LMIC where options for
potential prophylaxis or treatment such as defibrotide are not
readily available [80].
We recommend that high-risk patients in Setting 1 continue on
their same palliative chemotherapy used in induction for a total of
12months. In Setting 2, a tolerable consolidation therapy would be
4 cycles of modified POG 9341 regimen (Table IV), the French
CAdO/CE regimen for 2 cycles each [81] or cyclophosphamide/
topotecan for 6 cycles at 3–4–week intervals (Supplemental
Appendix III) followed by radiation therapy to the primary tumor
bed and residual bone metastases [68]. For Setting 3, if resources
are available for ASCT, then a peripheral blood stem cell (PBSC)
harvest could be performed after 2–5 cycles of induction. An earlier
timing of apheresis generally leads to improved feasibility in
obtaining sufficient PBSC numbers. If apheresis is not available,
autologous bone marrow could be collected and stored providing
that metastases have cleared. If resources to conduct ASCT are not
available, then a consolidation using outpatient-based cyclophos-
phamide/topotecan for 6 cycles at 3–4week intervals should be
considered (Supplemental Appendix III), as this combination was
successful in obtaining response in 30% of resistant or relapsed
patients [82]. An alternative therapy option would be to continue
induction therapy (POG 9341) for another 4 cycles. It is reasonable
to continue such chemotherapy with curative intent, as there were
still >20% EFS for patients treated with intensive consolidation
chemotherapy on the randomized CCG protocol [39]. We
recommend administration of 21.6Gy radiation to the primary
tumor bed and to residual bone metastases (fewer than six sites) at
the end of consolidation phase of therapy [83,84].
Minimal Residual Disease Therapy
Although myeloablative therapy has improved the outcome, up
to 40% of patients will relapse after this therapy. The CCG reported
the benefit of treating children after myeloablative therapy with a
differentiating agent, isotretinoin, with significant improvement in
EFS for all children post consolidation [58]. Isotretinoin for
6months is recommended in all settings as post-consolidation
therapy for patients who have achieved a complete remission
(Table V). It is not effective, and not recommended, for patients
with gross residual disease.Wewould urge particular caution before
prescribing isotretinoin for women of child-bearing age to review
risks and reinforce pregnancy prevention measures, as there is a
serious risk of birth defects in exposed pregnancies. Currently, theT
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anti-GD2 antibody Ch14.18 based trials, which has been shown to
further improve outcome, is not commercially available and
requires intensive supportive nursing care for administration, thus
limiting access in LMIC.
Recurrent/Progressive Disease and Alternative
Regimens
Despite intensive upfrontmultimodal therapy, over 50%of high-
risk neuroblastoma patients continue to relapse. After relapse these
patient have poor outcomes with 5-year OS< 10% [85]. Regimens
such as cyclophosphamide combined with topotecan or irinotecan
combined with temozolamide have demonstrated response rates for
refractory/relapse disease of 32% and 15%, respectively [82,86].
131I-mIBG therapy is also effective in relapsed disease, with a
30% response rate, but is available in few LMIC [87]. External
beam radiation therapy will often effectively control symptomatic
sites of disease [88]. Oral metronomic therapies may be options
for palliation for settings without access to camptothecins or
temozolomide [66,89]. Localized recurrence, particularly in low
and intermediate risk disease, may be salvageable with additional
surgery, radiation, and chemotherapy [26,27,90]. The determina-
tion of therapy is guided by timing of recurrence, previous therapies
received, individual patient factors and preferences of the family
and providers, in addition to the resources available within those
centers.
SUPPORTIVE CARE
Ability to care for children with fever and neutropenia is critical
in terms of life threatening complications. Therefore aggressive
multi-agent therapy should only be given at center capable of
ensuring that patients have rapid access to medical care and broad
spectrum antibiotic therapy either by providing affordable housing
in close proximity to the medical center or at a facility close to
patients’ home. It is equally important to educate on fever
management with handouts provided to patients and families at
each visit [13]. For Setting 3, a central venous catheter should
deliver intensive therapy and blood products. It is also recom-
mended in Setting 3 that a pediatric intensive care unit is located
within the treating center. Ongoing education should be provided
for nursing and medical assistants regarding the care of a child with
cancer. Red blood cell products and antibiotics should also be
readily available in all settings.
ADVANCING TREATMENT INTENSITY
The optimal intensity of therapy at each institution should be
determined based on the center’s own toxicity data, including grade
3 or 4 infection, sepsis, renal impairment, and death. Review of
relapses may also guide the decision to adjust therapy, since
reduction of intensity may produce a modest decrease in toxic death
but a larger increase in relapse. HIC currently report toxic death
rates below 5% for both induction and consolidation therapies [91].
A toxic death rate >5% for induction or 10% for consolidation
should trigger careful assessment and use of lower treatment
intensity if supportive care cannot be improved. Reviewing
institutional data on abandonment rates may help guide practices
to promote patient adherence.
CONCLUSION
Risk classification using an adapted approach that takes into
consideration limitations in diagnostic imaging and tumor biology
allows risk assignment for children with neuroblastoma, regardless
of their setting, and selection of feasible and appropriate treatment.
This approach does not preclude active efforts to implement the full
range of capabilities in every pediatric cancer unit, but can improve
outcomes for those patients who must be treated with the current
resources.
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